Do IDNA and PBE hold the same stocks?

By their latest filings, 18% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.

Which is more different from the S&P 500, IDNA or PBE?

IDNA has 27% of its weight in S&P 500 names and PBE has 32%, so IDNA differs more from the index.

Which is cheaper, IDNA or PBE?

IDNA charges 0.47% a year and PBE charges 0.59%, so IDNA is cheaper. Fees come from each fund's prospectus.

Data as of Nov 4, 2026.

Thematic ETFs

IDNA vs PBE: Holdings Overlap & Returns

Share on X Download as PDF

Over the year to Nov 4, 2026, IDNA returned +81.1% to PBE's +44.2%; 18% of their weight is in the same names.

askIQ about this page

askIQ about IDNA and PBE

Net assets on Nov 3, 2026: $340m for iShares Genomics Immunology and Healthcare ETF and $442m for Invesco Biotechnology & Genome ETF.

IDNA on its own →PBE on its own →

At a glance

27.4%

IDNA in the S&P 500

32.3%

PBE in the S&P 500

+81.1%

IDNA total return, 1 year

+44.2%

PBE total return, 1 year

IDNA · 1 year to Nov 4, 2026 73% of its weight is outside the S&P 500

27% of IDNA's weight is in S&P 500 companies and 73% is outside the index. Holdings as of Nov 3, 2026.

PBE · 1 year to Nov 4, 2026 68% of its weight is outside the S&P 500

32% of PBE's weight is in S&P 500 companies and 68% is outside the index. Holdings as of Nov 3, 2026.

Pair scorecard

IDNA costs 0.12 points a year less; their one-year returns differ by 36.9 points; PBE is 1.3 times larger.

IDNA vs PBE: Holdings Overlap & Returns
Measure	IDNA	PBE
Return
Measure	IDNA	PBE
Total return, 1 year	+81.1%	+44.2%
Drawdown
Measure	IDNA	PBE
Below its all-time high	16.5%, high on Sep 2, 2021
Benchmark
Measure	IDNA	PBE
What it tracks	Genomics and gene editing	Biotech
Cost and size
Measure	IDNA	PBE
Expense ratio	0.47%	0.59%
Net assets, as of Nov 3, 2026	$340m	$442m
Holdings
Measure	IDNA	PBE
Holdings in common	18%

Method

Risk and return

Jun 21, 2019 to Oct 30, 2026 · 384 weekly returns

IDNA PBE

Return

Total return edge PBE +69.5% +95.6%

Annualized edge PBE +7.4% +9.5%

Price return edge PBE +59.6% +91.2%

Risk

Volatility edge PBE 30.1% 23.7%

Max drawdown edge PBE −68.1% −35.9%

Risk-adjusted

Sharpe edge PBE 0.29 0.38

Sortino edge PBE 0.44 0.57

Calmar edge PBE 0.11 0.26

Reading

From Jun 2019 to Oct 2026, PBE returned more: +95.6% to +69.5%. PBE swung less: 23.7% to 30.1%. PBE fell less at its worst: −35.9% to −68.1%.

Full scorecard

9 measures, with how each is measured Open ↓

Risk and return: IDNA vs PBE: Holdings Overlap & Returns
Measure	IDNA	PBE	Edge	How it is measured
Return
Total return	+69.5%	+95.6%	PBE	Price change plus distributions, reinvested.
Annualized	+7.4%	+9.5%	PBE	Total return as a yearly rate.
Price return	+59.6%	+91.2%	PBE	Price change alone, distributions left out.
Risk
Volatility	30.1%	23.7%	PBE	Spread of weekly returns, annualized. Lower is steadier.
Downside deviation	20.2%	16.0%	PBE	Like volatility, counting only weeks below the Treasury bill rate.
Max drawdown	−68.1%	−35.9%	PBE	Deepest fall from a high to the low after it.
Risk-adjusted
Sharpe	0.29	0.38	PBE	Return above Treasury bills per unit of volatility.
Sortino	0.44	0.57	PBE	Return above Treasury bills per unit of downside deviation.
Calmar	0.11	0.26	PBE	Annualized return divided by the max drawdown.

Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 384 weekly returns. Cash rate: the 13-week Treasury bill.

What they share

18%

By the books each fund has filed, IDNA and PBE hold 18% of their money in the same securities at the same weight. Holdings dated Nov 3, 2026.

50%

0 half 100%

half

18% in common

Positions both hold · largest shared weight first IDNA PBE

REGENERON PHARMACEUTICALS 4.24% 5.62%

MODERNA 13.33% 3.78%

EXELIXIS INC 3.80% 3.35%

VERTEX PHARMACEUTICALS 3.29% 4.62%

INCYTE CORP 3.18% 2.38%

NOVAVAX 1.32% 2.69%

Only in one fund ↓

Only in IDNA

GENMAB 6.26%

TWIST BIOSCIENCE 5.61%

BAYER AG 3.85%

TAKEDA PHARMACEUTICAL 3.77%

REVOLUTION MEDICINES 3.60%

CARIS LIFE SCIENCES 3.50%

MERCK & CO INC 3.32%

ROCHE PS PAR AG 3.20%

Only in PBE

Natera Inc 5.56%

Biogen Inc 5.43%

Gilead Sciences Inc 5.42%

Royalty Pharma PLC 5.15%

Illumina Inc 5.10%

Amgen Inc 5.02%

Halozyme Therapeutics Inc 3.09%

United Therapeutics Corp 3.05%

Check overlap with more funds →

Window by window

Window by window: IDNA vs PBE: Holdings Overlap & Returns
	Total return
Window	IDNA	PBE
3 months	+32.4%	+14.2%
6 months	+45.6%	+27.1%
1 year	+81.1%	+44.2%
3 years	+134.8%	+90.4%
Since launchNot the same days: IDNA Jun 2019 · PBE Jun 2005	+88.1%	+650.5%

Open this comparison in the app →

Side by side

IDNA iShares Genomics Immunology and Healthcare ETF · Holds 52 stocks in genomics and gene editing, 27% of its weight in S&P 500 companies PBE Invesco Biotechnology & Genome ETF · Holds 32 stocks in biotech, 32% of its weight in S&P 500 companies

Issuer iShares Invesco

Theme Genomics and gene editing Biotech

In the S&P 500 27.4% 32.3%

Active share vs the S&P 500 99.1% 99.0%

In the Nasdaq-100 7.5% 20.7%

Holdings 52 32

Top ten, share of the fund 51.3% 49.1%

Expense ratio 0.47% 0.59%

Fee for the differing part 0.47% 0.60%

Total return, 1 year +81.1% +44.2%

vs its benchmark not measured not measured

Below its high −16.5% 0.0%

Net assets, as of Nov 3, 2026 $340m $442m

As of Nov 4, 2026. Source: ETFIQ.

18% of the two portfolios are the same securities at the same weight.

Client brief:

The two-page PDF for this pair is coming. Save the comparison to follow its changes. Free. It needs an email sign-in, once.

Your saved page · Privacy.

Alert

About each fund

IDNA

By weight, 27% of IDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 51% of the fund across 52 positions, as published by its issuer for Nov 3, 2026. Over the year to Nov 4, 2026 the fund returned +81.1% with distributions reinvested. It sits 16.5% below its all-time high of Sep 2, 2021.

PBE

By weight, 32% of PBE's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 49% of the fund across 32 positions, as published by its issuer for Nov 3, 2026. Over the year to Nov 4, 2026 the fund returned +44.2% with distributions reinvested.

Questions people ask

Do IDNA and PBE hold the same stocks?: By their latest filings, 18% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, IDNA or PBE?: IDNA has 27% of its weight in S&P 500 names and PBE has 32%, so IDNA differs more from the index.
Which is cheaper, IDNA or PBE?: IDNA charges 0.47% a year and PBE charges 0.59%, so IDNA is cheaper. Fees come from each fund's prospectus.

Other comparisons

IDNA vs IBBQ IDNA vs XBI IDNA vs IBB IDNA vs BBH PBE vs ARKG PBE vs GNOM PBE vs GNMX PBE vs BBC

Where to next

All thematic ETFs ranked by the S&P 500 Difference Score →How the scores are computed →IDNA on its own →PBE on its own →IDNA dividend history →IDNA holdings →PBE dividend history →PBE holdings →Method →Standards and sources →

Sources and dates

IDNA filings on SEC EDGAR ↗

IDNA prospectus with the expense ratio (SEC) ↗

iShares page for IDNA ↗

PBE filings on SEC EDGAR ↗

PBE prospectus with the expense ratio (SEC) ↗

Invesco page for PBE ↗

Links are sources, not endorsements. A comparison is not a recommendation.

How this is computed

Overlap adds up the smaller of the two weights for each security both funds hold.

Every number is an ETFIQ calculation with distributions reinvested.

Cite this pageCitation, APA and Markdown

ETFIQ, IDNA against PBE, data as of Nov 4, 2026. https://etfiq.com/compare/themes/idna-vs-pbe

Open data →

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.